DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
The generic ingredient in HETLIOZ is tasimelteon. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the tasimelteon profile page.
Generic Entry Opportunity Date for 205677
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 205677
|Mechanism of Action||Melatonin Receptor Agonists |
Profile for product number 001
|Approval Date:||Jan 31, 2014||TE:||RLD:||Yes|
|Regulatory Exclusivity Expiration:||Jan 31, 2021|
|Regulatory Exclusivity Use:||TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER|
|Patent:||Start Trial||Patent Expiration:||Feb 12, 2035||Product Flag?||Y||Substance Flag?||Y||Delist Request?|
|Patent:||Start Trial||Patent Expiration:||Jan 25, 2033||Product Flag?||Substance Flag?||Delist Request?|
|Patented Use:||TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH CYP1A2 STRONG INHIBITORS|
Complete Access Available with Subscription